EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieOpen Access · CC BY 4.0

Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open‐Label, Nonrandomized Controlled Trial

Huimin Li, Ming Wei, Xiaofeng Zhu, Xiu Yang, Qiang Tong, Qiu Han iD

Brain and Behavior · 2025

DOI: 10.1002/brb3.70806 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Brain and Behavior, 2025. Verfasst von Huimin Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jian…. Hauptthemen laut MEDLINE: Parkinson Disease, Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Huai'an First People's Hospital innovation team project, Xuzhou Medical University science and technology development fund surface project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX‐A) in alleviating neuropsychiatric symptoms among PD patients.

Methods

This is an open‐label, nonrandomized controlled trial. The subscales of the Cornell Medical Index, including somatization, anxiety, depression, maladjustment, sensitivity, anger, and tension, were used to evaluate neuropsychiatric symptoms. The study compared neuropsychiatric health status among 97 PD patients with neuropsychiatric symptoms, divided into two groups: BTX‐A ( n = 58) and citalopram hydrobromide (CH; n = 39). The BTX‐A group received local injections targeting the bilateral glabella, orbicularis oculi muscle, forehead, bilateral lateral canthus, and temporal area. Patients in the CH group received daily doses ranging from 10 to 40 mg. The efficacy of BTX‐A was assessed before and eight weeks after treatment, with outcomes compared to those of the CH group.

Results

The BTX‐A group showed significant reductions in somatization ( p = 0.028), tension ( p < 0.001), anxiety ( p = 0.001), depression ( p = 0.002), sensitivity ( p = 0.006), and total scores ( p = 0.009) at 8 weeks after treatment. Both the BTX‐A and CH groups demonstrated significant reductions in neuropsychiatric symptoms, with BTX‐A showing comparable efficacy to CH ( p > 0.05 for all parameters). Additionally, both groups showed comparable neuropsychiatric symptom improvement rates (64.3% vs. 73.7%, p > 0.05). These rates were calculated based on reductions in overall neuropsychiatric symptom severity scores.

Conclusions

In summary, BTX‐A demonstrates efficacy in reducing multiple neuropsychiatric symptoms (such as tension, anxiety, depression, sensitivity, etc.) in PD, with comparable effectiveness to CH, supporting its consideration as an alternative therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseBotulinum Toxins, Type ANeuromuscular AgentsHumansMaleFemaleAgedMiddle AgedTreatment OutcomeCitalopramAnxietyDepressionFacial Muscles

Stichwörter der Autor:innen

Cornell Medical IndexParkinson's diseasebotulinum toxin Aneuropsychiatric symptoms

Substanzen

Botulinum Toxins, Type ACitalopramNeuromuscular Agents

Autor:innen und Institutionen

  • Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.

ORCID-Profile: Qiu Han

Förderung

  • Huai'an First People's Hospital innovation team project
  • Xuzhou Medical University science and technology development fund surface project

Zitieren

APA

Li, H., Wei, M., Zhu, X., Yang, X., Tong, Q., & Han, Q. (2025). Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open‐Label, Nonrandomized Controlled Trial. Brain and Behavior. https://doi.org/10.1002/brb3.70806

Vancouver

Li H, Wei M, Zhu X, Yang X, Tong Q, Han Q. Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open‐Label, Nonrandomized Controlled Trial. Brain and Behavior. 2025. doi:10.1002/brb3.70806

BibTeX
@article{Li2025,
  author = {Li, Huimin and Wei, Ming and Zhu, Xiaofeng and Yang, Xiu and Tong, Qiang and Han, Qiu},
  title = {Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open‐Label, Nonrandomized Controlled Trial},
  journal = {Brain and Behavior},
  year = {2025},
  doi = {10.1002/brb3.70806}
}
Kostenlos starten →